Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Pediatric Hematology/Oncology
•
Lymphoma
•
Hodgkin Lymphoma
•
Primary Care
What cardiac surveillance would you do for an asymptomatic male patient with a remote history of mantle field radiation for Hodgkin's lymphoma?
Answer from: Radiation Oncologist at NCI-Designated Cancer Center
I would follow the long-term follow-up guidelines from COG based on heart dose - Children's Oncology Group (survivorshipguidelines.org)
Sign In
or
Register
to read more
22730
Related Questions
In pediatric patients with Hodgkin lymphoma who have a partial response after chemotherapy and multiple disease sites above and below the diaphragm, how do you approach radiotherapy planning considering cumulative dose and toxicity?
How do you consider SBRT relative to other emerging therapies for pediatric sarcomas, such as proton therapy or immunotherapy, in terms of efficacy and safety?
What criteria would you consider to select patients for 20 Gy consolidative RT in DLBCL/HGBL?
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
What radiation dose and margins would you recommend for treatment of a progressive cerebellar glioma with BCOR/BCOR1 fusion after initial subtotal resection with residual disease adjacent to the posterior brainstem?
How would you manage a rare presentation of an older adult after gross total resection of an "infant-type hemispheric glioma" of the left frontal lobe, IDH1 negative and negative for MYB fusions?
How do you approach patients who are inappropriately worried/fixated on a test result that is flagged as abnormal but not clinically significant?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?